

Supplementary table 1. Baseline characteristics

Characteristics	n	Overall (n=129)	Maintenance (n=68)	Space (n=61)
Age at inclusion (years), mean (SD)	129	55.3 (11.51)	56.62 (11.95)	53.84 (10.92)
Sex (female), n (%)	129	100 (77.52%)	49 (72.06%)	51 (83.61%)
Disease duration (years), mean (SD)	129	10.18 (8.24)	11.18 (8.78)	9.07 (7.5)
Methotrexate combination, n (%)	129	89 (68.99%)	46 (67.65%)	43 (70.49%)
Adalimumab	129	60 (46.51%)	33 (48.53%)	27 (44.26%)
ACPA positivity, n (%)	111	87 (78.38%)	43 (76.79%)	44 (80.00%)
RF positivity, n (%)	112	78 (69.64%)	41 (70.69%)	37 (68.52%)
DAS 28-CRP at inclusion, mean (SD)	129	1.8 (0.55)	1.7 (0.51)	1.92 (0.57)
Tender joint count, median [Q1, Q3]	129	0 [0, 1]	0 [0, 0]	0 [0, 1]
Swollen joint count, median [Q1, Q3]	129	0 [0, 0]	0 [0, 0]	0 [0, 0]
CRP at inclusion (mg/l), mean (SD)	128	2.77 (1.84)	2.85 (1.82)	2.68 (1.87)
ESR (mm), mean (SD)	128	12.59 (9.47)	12.4 (10.36)	12.8 (8.48)
Calprotectin (ng/ml), mean (SD)	129	1526.3 (1037.93)	1419.35 (846.68)	1645.52 (1212.56)
Relapse	128	77 (60.16%)	31 (46.27%)	46 (75.41%)

ACPA: anti-citrullinated protein antibody, RF: rheumatoid factor, DAS28-CRP: disease activity score 28-CRP, CRP: C-reactive protein, ESR: erythrocyte sedimentation rate.

Supplementary Table 2. Baseline factors associated with disease relapse in sustained remission rheumatoid arthritis (Cox regression models)

Baseline characteristics	All patients		Maintenance arm		Spacing arm	
	Univariate HR (95% CI; p-value)	Multivariate HR (95% CI; p-value)	Univariate HR (95% CI; p-value)	Multivariate HR (95% CI; p-value)	Univariate HR (95% CI; p-value)	Multivariate HR (95% CI; p-value)
Calprotectin	1.00 (0.99, 1.00); p=0.63	1.00 (0.99, 1.00); p=0.47	1.00 (0.99, 1.00); p=0.88	0.99 (0.99, 1.00); p=0.46	1.00 (0.99, 1.00); p=0.78	0.99 (0.99, 1.00); p=0.77
RF positive	1.93 (1.10, 3.39); p=0.02	2.53 (1.39, 4.59); p=0.001	2.21 (0.83, 5.86); p=0.09	2.37 (0.89, 6.31); p=0.06	2.03 (1.01, 4.07); p=0.04	3.13 (1.37, 7.11); p=0.005
ACPA positive	1.09 (0.61, 1.97); p=0.77		0.72 (0.30, 1.72); p=0.47		1.60 (0.71, 3.63); p=0.23	
CRP	0.99 (0.88, 1.12); p=0.93		1.08 (0.89, 1.30); p=0.44		0.94 (0.81, 1.10); p=0.44	
ESR	1.01 (0.99, 1.03); p=0.39		1.01 (0.98, 1.04); p=0.56		1.00 (0.98, 1.04); p=0.63	
Neutrophils	1.00 (0.99, 1.00); p=0.81		1.00 (0.99, 1.00); p=1.00		1.00 (0.99, 1.00); p=0.45	
Female	1.56 (0.87, 2.78); p=0.12	1.01 (0.54, 1.89); p=0.97	0.98 (0.46, 2.15); p=0.98		2.27 (0.90, 5.77); p=0.05	1.63 (0.61, 4.33); p=0.30
Disease duration	1.02 (0.99, 1.05); p=0.17	1.01 (0.98, 1.04); p=0.37	1.02 (0.98, 1.06); p=0.42		1.04 (1.00, 1.07); p=0.05	1.01 (0.96, 1.05); p=0.76
Erosive RA	0.97 (0.49, 1.95); p=0.94		0.81 (0.28, 2.31); p=0.70		1.19 (0.47, 3.00); p=0.71	
Adalimumab	1.58 (1.00, 2.47); p=0.046	1.91 (1.12, 3.24); p=0.02	1.62 (0.79, 3.20); p=0.18	1.50 (0.66, 3.42); p=0.33	1.71 (0.96, 3.07); p=0.07	2.38 (1.09, 5.19); p=0.03
Methotrexate user	0.99 (0.62, 1.60); p=0.98		0.74 (0.36, 1.53); p=0.43		1.26 (0.66, 2.39); p=0.47	
Spacing	2.16 (1.37, 3.42); p=0.001	2.54 (1.48, 4.36); p=0.001	NA	NA	NA	NA
Joint swollen count	1.09 (0.69, 1.72); p=0.70		0.87 (0.40, 1.88); p=0.71		1.49 (0.80, 2.77); p=0.24	
Joint tender count	1.11 (0.96, 1.28); p=0.19	1.06 (0.92, 1.23); p=0.44	1.09 (0.80, 1.49); p=0.60		1.06 (0.90, 1.25); p=0.48	
DAS28-CRP	1.53 (1.00, 2.35); p=0.04	1.10 (0.66, 1.83); p=0.72	1.68 (0.83, 3.41); p=0.14	1.67 (0.72, 3.89); p=0.22	1.15 (0.69, 1.90); p=0.58	

RF: rheumatoid factor, ACPA: anti-citrullinated protein antibody, CRP: C-reactive protein, ESR: erythrocyte sedimentation rate, RA: rheumatoid arthritis, DAS28-CRP: disease activity score 28-CRP, HR: hazard ratio, NA: not applicable. A univariate and multivariate analyses, using the Cox regression models were performed. All variable with p-value <0.20 were selected for the multivariate analysis in addition to serum calprotectin level. p values <0.05 are marked in bold.